Rating Change
Craig-Hallum reiterated its Buy rating on Myriad Genetics, Inc. (NASDAQ:MYGN) on October 02, 2026.
reiterateNASDAQ:MYGN
Craig-Hallum Reiterates Buy Rating on Myriad Genetics, Inc. (MYGN)
Craig-Hallum reiterated its Buy rating on Myriad Genetics, Inc. (NASDAQ:MYGN) on October 02, 2026.
At publication ·
What changed
Myriad Genetics, Inc. (NASDAQ:MYGN) · reiterate
- Firm
- Craig-Hallum
- Rating
- Buy to Buy
- Price at event
- $4.46
- Market capitalization
- $680.9M
At a glance
Key takeaways
- Craig-Hallum reiterated a Buy rating on Myriad Genetics (MYGN) on October 2, 2026, though the stock trades at $4.46 with a market capitalization of $680.9 million.
Market Context
Myriad Genetics, Inc. operates in the Healthcare sector. The stock currently trades at $4.46 with a market capitalization of $680.9M. The stock has declined 41.3% over the past 52 weeks.
Analyst coverage from Craig-Hallum provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Myriad Genetics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Myriad Genetics, Inc.
Among the 10 most recent ratings: 1 Buy, 8 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 02, 2026 | Craig-Hallum | Buy | N/A |
| Sep 09, 2026 | UBS | Neutral | N/A |
| Sep 01, 2026 | Piper Sandler | Underweight | N/A |
| Aug 18, 2026 | Stephens & Co. | Equal-Weight | N/A |
| Aug 03, 2026 | Wells Fargo | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View MYGN Stock Page
Frequently Asked Questions
What does the Buy rating mean for MYGN?
A rating of Buy from Craig-Hallum reflects the analyst's outlook on Myriad Genetics, Inc. (NASDAQ:MYGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MYGN forecast page.